A systematic review of the cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer

被引：0
|
作者：
Frank, M. [1 ]
Lange, A. [1 ]
Prenzler, A. [1 ]
Kirstein, M. [2 ]
Vogel, A. [2 ]
von der Schulenburg, Graf J. -M [1 ]
机构：
[1] CHERH, Hannover, Germany
[2] Hannover Med Sch, Klin Gastroenterol Hepatol & Endokrinol, D-30623 Hannover, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study
    Wen, Feng
    Yang, Yu
    Zhang, Pengfei
    Zhang, Jian
    Zhou, Jing
    Tang, Ruilei
    Chen, Hongdou
    Zheng, Hanrui
    Fu, Ping
    Li, Qiu
    CANCER BIOLOGY & THERAPY, 2015, 16 (11) : 1577 - 1584
  • [22] Systematic Review on Infusion Reactions Associated with Chemotherapies and Monoclonal Antibodies for Metastatic Colorectal Cancer
    Song, Xue
    Long, Stacey R.
    Barber, Beth
    Kassed, Cheryl A.
    Healey, Marcus
    Jones, Clare
    Zhao, Zhongyun
    CURRENT CLINICAL PHARMACOLOGY, 2012, 7 (01): : 56 - 65
  • [23] COST-EFFECTIVENESS OF COMPUTED TOMOGRAPHY COLONOGRAPHY IN COLORECTAL CANCER SCREENING: A SYSTEMATIC REVIEW
    Hanly, Paul
    Skally, Mairead
    Fenlon, Helen
    Sharp, Linda
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 415 - 423
  • [24] Variation in estimates of cost-effectiveness for colorectal cancer (CRC) screening: A systematic review
    Marshall, JK
    Marshall, DA
    Brazier, N
    O'Brien, BJ
    GASTROENTEROLOGY, 2003, 124 (04) : A620 - A620
  • [25] The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation
    Takeda, A. L.
    Jones, J.
    Loveman, E.
    Tan, S. C.
    Clegg, A. J.
    HEALTH TECHNOLOGY ASSESSMENT, 2007, 11 (19) : 1 - +
  • [26] Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA
    Kang, Dong-Won
    Lynn, Patricio B.
    Wang, Li
    Zhou, Shouhao
    Shen, Chan
    PHARMACOECONOMICS-OPEN, 2024, : 93 - 101
  • [27] Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Chan, Kelvin K. W.
    Virik, Kiran
    Hammerman, Ariel
    Brenner, Baruch
    Flowers, Christopher R.
    Hall, Peter S.
    ONCOLOGIST, 2017, 22 (06): : 694 - 699
  • [28] Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer
    Sherman, Scott K.
    Lange, Joel J.
    Dahdaleh, Fadi S.
    Rajeev, Rahul
    Gamblin, T. Clark
    Polite, Blase N.
    Turaga, Kiran K.
    JAMA ONCOLOGY, 2019, 5 (02) : 236 - 242
  • [29] Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer.
    Goldstein, Daniel A.
    Ahmad, Bilal B.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [30] Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab and panitumumab) in the treatment of metastatic colorectal cancer: Systematic review and metanalysis.
    Silva, Wania Cristina
    Lima, Ellias Magalhaes Abreu
    Araujo, Vania Eloisa
    Santos, Jessica Barreto Ribeiro
    Silva, Michael Ruberson Ribeiro
    Acurcio, Francisco Assis
    Cherchiglia, Mariangela Leal
    Andrade, Eli Iola Gurgel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345